| 抗新型冠状病毒药物的研究进展 |
| |
| 引用本文： | 郑曦,张晨阳,陈思充,焦光宇,郝丽英.抗新型冠状病毒药物的研究进展[J].实用药物与临床,2021(2). |
| |
| 作者姓名： | 郑曦 张晨阳 陈思充 焦光宇 郝丽英 |
| |
| 作者单位： | 中国医科大学药学院药物毒理教研室;中国医科大学附属盛京医院呼吸与危重症医学科 |
| |
| 基金项目： | 国家自然基金(31471091,81170068);中国医科大学新冠肺炎疫情防控相关科研攻关项目(2020-07)。 |
| |
| 摘 要： | 新型冠状病毒肺炎(Coronavirus disease 2019,COVID-19)具有很强的传染性和很高的致病率。目前,对于新型冠状病毒(Severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)尚没有特异性的抗病毒药物,临床上根据以往抗冠状病毒用药经验以及“老药新用”原则,应用现有药物进行治疗。本文根据抗冠状病毒药物的作用机制,对临床正在使用和具有潜在抗SARS-CoV-2作用的药物及在研化合物进行综述,以期为COVID-19治疗的合理用药及抗SARS-CoV-2的新药研发提供理论依据及新思路。
|
| 关 键 词： | SARS-CoV-2 COVID-19 抗病毒药物 作用机制 |
Research progress in anti-SARS-CoV-2 drugs |
| |
| ZHENG Xi,ZHANG Chen-yang,CHEN Si-chong,JIAO Guang-yu,HAO Li-ying.Research progress in anti-SARS-CoV-2 drugs[J].Practical Pharmacy and Clinical Remedies,2021(2). |
| |
| Authors: | ZHENG Xi ZHANG Chen-yang CHEN Si-chong JIAO Guang-yu HAO Li-ying |
| |
| Institution: | (Department of Drug Toxicology,College of Pharmacy,China Medical University,Shenyang 110122,China;Respiratory Department and Intensive Care Unit,Shengjing Hospital of China Medical University,Shenyang 110004,China) |
| |
| Abstract: | Coronavirus disease 2019(COVID-19)is highly infectious and highly pathogenic.At present,there are no specific antiviral drugs for severe acute respiratory syndrome coronavirus 2(SARS-CoV-2).According to the past experience of using anti-coronavirus drugs and the principle of“new use of old drugs”,the existing drugs are used in the clinical antiviral therapy for SARS-CoV-2.In this paper,based on the acting mechanism of anti-coronavirus drugs,the clinical and potential use of anti-SARS-CoV-2 drugs and the compounds under development were reviewed in order to provide theoretical basis and new ideas for the rational use of drugs in COVID-19 treatment and the development of new drugs against SARS-CoV-2. |
| |
| Keywords: | SARS-CoV-2 COVID-19 Antiviral drugs Mechanism |
| 本文献已被 维普 等数据库收录！ |
|
